Article info
PDFInterstitial lung disease
Original research
Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects
- Correspondence to Dr Catherine Overed-Sayer, Regeneration, Research and Early Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, CB21 6GH, United Kingdom; catherine.overed-sayer{at}astrazeneca.com
Citation
Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects
Publication history
- Received August 21, 2019
- Revised April 17, 2020
- Accepted May 1, 2020
- First published July 24, 2020.
Online issue publication
September 01, 2022
Article Versions
- Previous version (17 August 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.